{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Low-Grade+Lymphoma&page=4", "query": { "condition": "Low-Grade Lymphoma", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 132, "total_pages": 14, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Low-Grade+Lymphoma&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Low-Grade+Lymphoma&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T10:17:55.615Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00014235", "title": "Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acute Myeloid Leukemia/Transient Myeloproliferative Disorder", "Acute Undifferentiated Leukemia", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Blastic Plasmacytoid Dendritic Cell Neoplasm", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Burkitt Lymphoma", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "Childhood Myelodysplastic Syndromes", "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", "Chronic Myelomonocytic Leukemia", "Cutaneous B-cell Non-Hodgkin Lymphoma", "de Novo Myelodysplastic Syndromes", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Juvenile Myelomonocytic Leukemia", "Mast Cell Leukemia", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Nodal Marginal Zone B-cell Lymphoma", "Noncutaneous Extranodal Lymphoma", "Peripheral T-cell Lymphoma", "Post-transplant Lymphoproliferative Disorder", "Previously Treated Myelodysplastic Syndromes", "Primary Systemic Amyloidosis", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Refractory Multiple Myeloma", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Stage II Multiple Myeloma", "Stage III Multiple Myeloma", "T-cell Large Granular Lymphocyte Leukemia", "Testicular Lymphoma", "Untreated Adult Acute Lymphoblastic Leukemia", "Untreated Adult Acute Myeloid Leukemia", "Untreated Childhood Acute Lymphoblastic Leukemia", "Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "74 Years", "sex": "ALL", "summary": "Up to 74 Years" }, "enrollment_count": 160, "start_date": "2000-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2020-01-21", "last_synced_at": "2026-11-15T10:17:55.615Z", "location_count": 9, "location_summary": "Tucson, Arizona • Duarte, California • Stanford, California + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Portland", "state": "Oregon" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00014235" }, { "nct_id": "NCT00003993", "title": "Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "bryostatin 1", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute on Aging (NIA)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "1999-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-04-29", "last_synced_at": "2026-11-15T10:17:55.615Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003993" }, { "nct_id": "NCT03233204", "title": "Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma", "Low Grade Glioma", "Malignant Glioma", "Recurrent Childhood Central Nervous System Neoplasm", "Recurrent Childhood Ependymoma", "Recurrent Childhood Malignant Germ Cell Tumor", "Recurrent Childhood Non-Hodgkin Lymphoma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Childhood Soft Tissue Sarcoma", "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Recurrent Glioma", "Recurrent Hepatoblastoma", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Malignant Solid Neoplasm", "Recurrent Medulloblastoma", "Recurrent Neuroblastoma", "Recurrent Osteosarcoma", "Refractory Childhood Malignant Germ Cell Tumor", "Refractory Ependymoma", "Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Refractory Glioma", "Refractory Hepatoblastoma", "Refractory Langerhans Cell Histiocytosis", "Refractory Malignant Glioma", "Refractory Malignant Solid Neoplasm", "Refractory Medulloblastoma", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Osteosarcoma", "Refractory Primary Central Nervous System Neoplasm", "Refractory Rhabdomyosarcoma", "Refractory Soft Tissue Sarcoma", "Rhabdoid Tumor", "Wilms Tumor" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 6, "start_date": "2017-09-14", "completion_date": "2024-06-30", "has_results": true, "last_update_posted_date": "2024-12-11", "last_synced_at": "2026-11-15T10:17:55.615Z", "location_count": 111, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 88 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03233204" }, { "nct_id": "NCT00244855", "title": "Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Contiguous Stage II Grade 1 Follicular Lymphoma", "Contiguous Stage II Grade 2 Follicular Lymphoma", "Contiguous Stage II Marginal Zone Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Nodal Marginal Zone B-cell Lymphoma", "Noncontiguous Stage II Grade 1 Follicular Lymphoma", "Noncontiguous Stage II Grade 2 Follicular Lymphoma", "Noncontiguous Stage II Marginal Zone Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Marginal Zone Lymphoma", "Splenic Marginal Zone Lymphoma", "Stage I Grade 1 Follicular Lymphoma", "Stage I Grade 2 Follicular Lymphoma", "Stage I Marginal Zone Lymphoma", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Marginal Zone Lymphoma", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "pharmacological study", "type": "OTHER" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER", "BIOLOGICAL", "DRUG" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2004-05", "completion_date": "2011-08-29", "has_results": true, "last_update_posted_date": "2017-05-22", "last_synced_at": "2026-11-15T10:17:55.615Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00244855" }, { "nct_id": "NCT00143884", "title": "Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma, Low-Grade", "Lymphoma, Non-Hodgkin's", "Multiple Myeloma", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Reduced intensity conditioning", "type": "PROCEDURE" }, { "name": "Prophylactic donor leukocyte infusions", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 30, "start_date": "2000-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2007-04-23", "last_synced_at": "2026-11-15T10:17:55.615Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00143884" }, { "nct_id": "NCT01682746", "title": "Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain Tumor, Recurrent" ], "interventions": [ { "name": "Photofrin (porfimer sodium) & photodynamic therapy.", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Harry T Whelan, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "18 Years", "sex": "ALL", "summary": "6 Months to 18 Years" }, "enrollment_count": 5, "start_date": "2013-03", "completion_date": "2018-06-29", "has_results": false, "last_update_posted_date": "2019-02-25", "last_synced_at": "2026-11-15T10:17:55.615Z", "location_count": 1, "location_summary": "Wauwatosa, Wisconsin", "locations": [ { "city": "Wauwatosa", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01682746" }, { "nct_id": "NCT02924038", "title": "A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioma", "Malignant Glioma", "Astrocytoma, Grade II", "Oligodendroglioma", "Glioma, Astrocytic", "Oligoastrocytoma, Mixed" ], "interventions": [ { "name": "IMA950", "type": "BIOLOGICAL" }, { "name": "poly-ICLC", "type": "BIOLOGICAL" }, { "name": "Varlilumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Nicholas Butowski", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2017-04-03", "completion_date": "2022-12-31", "has_results": true, "last_update_posted_date": "2024-06-14", "last_synced_at": "2026-11-15T10:17:55.615Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02924038" }, { "nct_id": "NCT01371630", "title": "Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1", "B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative", "Burkitt-Like Lymphoma With 11q Aberration", "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "Recurrent B Acute Lymphoblastic Leukemia", "Recurrent Burkitt Lymphoma", "Refractory B Acute Lymphoblastic Leukemia", "Refractory Burkitt Lymphoma" ], "interventions": [ { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Inotuzumab Ozogamicin", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 276, "start_date": "2011-08-26", "completion_date": "2027-12-25", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-11-15T10:17:55.615Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01371630" }, { "nct_id": "NCT00006241", "title": "Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Low- or Intermediate-Grade Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "chemotherapy", "type": "DRUG" }, { "name": "in vitro-treated peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": null, "start_date": "2000-03", "completion_date": "2000-10", "has_results": false, "last_update_posted_date": "2011-11-30", "last_synced_at": "2026-11-15T10:17:55.615Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006241" }, { "nct_id": "NCT00003196", "title": "Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Noncutaneous Extranodal Lymphoma", "Peripheral T-cell Lymphoma", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Refractory Multiple Myeloma", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Stage II Multiple Myeloma", "Stage III Multiple Myeloma", "Testicular Lymphoma", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "chemotherapy", "type": "DRUG" }, { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "50 Years to 65 Years" }, "enrollment_count": 63, "start_date": "1997-09", "completion_date": "2002-04", "has_results": false, "last_update_posted_date": "2019-12-27", "last_synced_at": "2026-11-15T10:17:55.615Z", "location_count": 3, "location_summary": "Duarte, California • Stanford, California • Seattle, Washington", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003196" } ] }